-

QIAGEN’s QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria

  • Nigerian Ministry of Health publishes guidelines highlighting QIAGEN’s gold standard blood test for latent TB as part of their “test and treat” strategy to fight the disease
  • Largest economy in Africa is the first country to recommend only QuantiFERON®-TB Gold Plus as standard IGRA
  • High-risk population will now be screened for latent tuberculosis

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Nigeria, the country with the largest population in Africa and one of the world’s 30 high-disease burden countries for tuberculosis (TB), has published guidelines recommending QuantiFERON®-TB Gold Plus (QFT®-Plus) in screening for latent TB infection (LTBI) as part of Nigeria’s strategy to prevent the spread of tuberculosis. QIAGEN has partnered with Nigeria’s National Tuberculosis & Leprosy Control Program (NTBLCP) to adapt World Health Organisation (WHO) guidelines and provide guidance to healthcare professionals on dealing with latent TB. Nigeria is the first high-burden country to exclusively embrace modern blood tests, called interferon gamma release assays (IGRAs), for latent TB screening of at-risk individuals in tuberculosis control programs.

QIAGEN’s QuantiFERON®-TB Gold Plus to be adopted for latent TB testing in Nigeria

Share

“Nigeria is first in Africa to adopt the Global End TB strategy by incorporating TB prevention in their national TB guidelines. As a more comprehensive disease control approach, their new guidelines will take aim at the large silent reservoir of latent TB infection by testing and targeting those who are more likely to become tomorrow’s cases.” said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. “To finally provide both TB treatment and prevention for Nigerians is a major step forward towards global health equity and accelerating TB decline in Nigeria. We wholeheartedly congratulate Dr. Lawanson and Nigeria’s Ministry of Health.”

“We are proud to publish these new guidelines for LTBI screening for Nigeria, based on the WHO recommendation of 2018, as this is a crucial step to accelerate our efforts to fight latent and active tuberculosis in our country,” comments Dr. Adebola Lawanson, National Coordinator of the TB Programme, Federal Ministry Of Health of Nigeria. “The creation of these guidelines, and the input from QIAGEN, was a great opportunity to innovate our approach to testing and treatment of TB with the inclusion of IGRA testing. With these guidelines our healthcare professionals now have a holistic protocol on managing at risk individuals with latent TB to avoid progression to active TB, followed by antibiotic treatment of infected individuals.”

Please find the full press release here

Contacts

Investor Relations
John Gilardi, +49 2103 29 11711
Phoebe Loh, +49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676
e-mail: pr@QIAGEN.com

QIAGEN

NYSE:QGEN
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Summary
QIAGEN’s QuantiFERON®-TB Gold Plus to be adopted for latent TB testing in Nigeria
Release Versions
$Cashtags

Contacts

Investor Relations
John Gilardi, +49 2103 29 11711
Phoebe Loh, +49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676
e-mail: pr@QIAGEN.com

Social Media Profiles
More News From QIAGEN

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown. Solid ongoing trends among the growth pillars, which rose 7% CER,...

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo...

QIAGEN Appoints Mark Stevenson to Supervisory Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Ket...
Back to Newsroom